- Home
- NEWT vs RGNX Comparison
NEWT vs RGNX Comparison
Compare NEWT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- RGNX
- Stock Information
- Founded
- NEWT 1998
- RGNX 2008
- Country
- NEWT United States
- RGNX United States
- Employees
- NEWT N/A
- RGNX N/A
- Industry
- NEWT Major Banks
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEWT Finance
- RGNX Health Care
- Exchange
- NEWT Nasdaq
- RGNX Nasdaq
- Market Cap
- NEWT 340.9M
- RGNX 372.1M
- IPO Year
- NEWT N/A
- RGNX 2015
- Fundamental
- Price
- NEWT $13.02
- RGNX $7.37
- Analyst Decision
- NEWT Hold
- RGNX Strong Buy
- Analyst Count
- NEWT 3
- RGNX 12
- Target Price
- NEWT $14.67
- RGNX $36.00
- AVG Volume (30 Days)
- NEWT 160.0K
- RGNX 1.8M
- Earning Date
- NEWT 03-04-2025
- RGNX 02-25-2025
- Dividend Yield
- NEWT 5.84%
- RGNX N/A
- EPS Growth
- NEWT 22.62
- RGNX N/A
- EPS
- NEWT 1.68
- RGNX N/A
- Revenue
- NEWT $316,405,000.00
- RGNX $84,327,000.00
- Revenue This Year
- NEWT N/A
- RGNX $2.92
- Revenue Next Year
- NEWT $8.51
- RGNX $234.86
- P/E Ratio
- NEWT $7.75
- RGNX N/A
- Revenue Growth
- NEWT 38.64
- RGNX N/A
- 52 Week Low
- NEWT $10.07
- RGNX $6.56
- 52 Week High
- NEWT $15.49
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- NEWT 50.66
- RGNX 42.98
- Support Level
- NEWT $12.52
- RGNX $6.98
- Resistance Level
- NEWT $13.05
- RGNX $7.70
- Average True Range (ATR)
- NEWT 0.33
- RGNX 0.57
- MACD
- NEWT 0.06
- RGNX 0.02
- Stochastic Oscillator
- NEWT 83.21
- RGNX 35.53
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.